Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
|Articles|January 11, 2021
Pharmacy Times: Week of January 11 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Emily Cook, JD, a partner with McDermott Will & Emery, discussing the final 340B Administrative Dispute Resolution Rule (ADR Rule), which was recently released by the HHS and will be published in the Federal Register at a later date. Cook explains the changes in the final ADR Rule from the proposed rule that was previously discussed.
- An article that discusses monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of coronavirus disease 2019.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5